Picard Medical Showcases Leadership in Artificial Heart Innovation at THT 2026

Key Highlights from the Report

• Picard Medical, Inc. (NYSE American: PMI) and its subsidiary, SynCardia Systems, are reinforcing their position as a global leader in artificial heart technology at the prestigious Technology and Heart Failure Therapeutics (THT) 2026 conference in Boston.
• Vice President of Clinical Affairs, Dr. Andre Simon, is delivering three high-profile presentations, including new data on both the current SynCardia Total Artificial Heart (STAH) and the next-generation Emperor system.
• Key findings and advancements highlighted:
  • Additional clinical benefits of STAH beyond survival, such as organ recovery, quality of life improvements, and preservation of transplant opportunities.
  • Preclinical progress on the next-generation Emperor system—a fully implantable artificial heart designed to improve patient mobility and independence.
  • Updated registry data demonstrating sustained clinical success, improved outcomes when therapy is initiated earlier, and significant enhancements in quality of life for critically ill patients.
• Over 2,100 SynCardia implants: The STAH remains the only FDA and Health Canada-approved, and commercially available, total artificial heart, with unmatched clinical experience globally.

Important Details for Shareholders

• Innovation in Artificial Heart Technology: The Emperor system, showcased with first in vitro and in vivo data, represents a significant leap forward. Its fully implantable design eliminates the need for transdermal drivelines, which could revolutionize long-term patient outcomes and quality of life. This innovation positions Picard Medical at the forefront of the artificial heart market and signals a potentially transformative new product for the company.
• Clinical Data and Market Leadership: Updated registry analyses show that SynCardia’s technology not only saves lives but also stabilizes critically ill patients, enables organ recovery, improves functional status, and maintains transplant eligibility. These metrics are crucial for hospital adoption and payer support—both key drivers of revenue growth.
• Expansion Potential and Competitive Advantage: With more than 2,100 implants across 27 countries, SynCardia’s artificial heart is the most widely used and studied worldwide. This entrenched position, combined with ongoing innovation, could translate into greater market share and future revenue streams.
• Regulatory and Commercial Significance: The STAH is the only FDA- and Health Canada-approved device of its kind, providing a substantial barrier to entry for competitors and regulatory de-risking.
• Potential Price-Sensitive Implications:
  • If the Emperor system advances to human trials and maintains its early promise, it could be a major catalyst for share price appreciation.
  • Ongoing strong clinical outcomes data are likely to reinforce the company’s reputation and drive further adoption, potentially boosting sales and market value.
  • The focus on improved quality of life and long-term independence for patients may open new markets (e.g., durable support, not just bridge-to-transplant).

Detailed Summary of THT 2026 Presentations

1. “The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia’s Electromechanical Total Artificial Heart” (March 2, 4:15 PM EST):
   Dr. Simon will present early laboratory and preclinical data on the Emperor system, which aims to preserve the proven physiologic performance of the STAH in a fully implantable format. This system is intended to improve patient mobility, quality of life, and long-term independence by eliminating the need for external pneumatic drivelines.
2. “The Total Artificial Heart of the Future: My Wish List” (March 3, 3:28 PM EST):
   Dr. Simon will discuss future directions in artificial heart therapy, including earlier intervention, organ recovery, better patient selection, and the shift from bridge-to-transplant to durable, long-term support for end-stage heart failure patients.
3. “Beyond Survival: Defining Success After Total Artificial Heart Implantation” (March 4, 8:50 AM EST):
   This presentation will reveal new registry data showing that the benefits of STAH extend well beyond survival. Key findings include:
   • Sustained clinical success in critically ill patients.
   • Improved outcomes for patients implanted earlier in their disease progression.
   • Strong recovery potential even for patients initially not eligible for transplant.
   • Significant improvements in quality of life after postoperative recovery.
   • Renal and neurological outcomes remain important for long-term success.

Company and Market Context

Picard Medical, through its SynCardia subsidiary, develops, manufactures, and commercializes the only commercially available total artificial heart for end-stage heart failure. The company’s technology is FDA and Health Canada-approved, with over 2,100 implants in 27 countries, making it the most widely used and studied device in the world.

The THT 2026 conference, sponsored by the Cardiovascular Research Foundation, is a premier global event gathering leaders in advanced heart failure devices, therapies, and research. Picard Medical’s prominent role and new data releases here underscore its innovation leadership and market momentum.

Investor Contacts and Information

Investors:
Eric Ribner, Managing Director, LifeSci Advisors LLC
[email protected]
Picard Medical, Inc./SynCardia Systems, LLC
[email protected]

General/Media:
Brittany Lanza
[email protected]

For more information, visit www.picardmedical.com.

Disclaimer

This article contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated. Investors should review the company’s filings with the SEC for a full discussion of risks, and should not rely solely on this article for investment decisions. The author does not hold a position in Picard Medical, Inc. at the time of publication.

View Picard Medical, Inc. Historical chart here